Oppenheimer raised the firm’s price target on Pharming (PHAR) to $39 from $30 and keeps an Outperform rating on the shares following quarterly ...

Pharming Group (PHGUF) reports a 21% increase in full-year revenue, strategic Abliva acquisition, and positive financial outlook for 2025.

The European market has recently experienced a slight downturn, with the pan-European STOXX Europe 600 Index ending lower amid ongoing uncertainty about U.S. trade policy. Despite these challenges, ...

Full Year 2024 Results Key Financial Results Revenue: US$297.2m (up 21% from FY 2023).

Discover key insights from Pharming Group's Q4 2024 earnings call. Explore strong revenue growth, RUCONEST & Joenja drivers, and 2025 strategic priorities.

Dutch biopharma company Pharming (Euronext Amsterdam: PHARM) has reported a 21% increase in revenue for 2024, reaching $297 ...

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...

A BioSpace analysis of all 80 priority review vouchers that have been handed out across the three FDA programs that offer ...

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of ...

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenu ...

Pharming Group (NASDAQ:PHAR – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $8.54, but opened at $9.06. Pharming Group shares last traded at $9.15, ...

For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [email protected] or your Roth ...